VYYRF (Voyageur Pharmaceuticals) LT-Debt-to-Total-Asset: 0.00 (As of Feb. 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
18 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals LT-Debt-to-Total-Asset?

Voyageur Pharmaceuticals VYYRF 18 LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Voyageur Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Feb. 2026 was 0.00.

Voyageur Pharmaceuticals's long-term debt to total assets ratio declined from Feb. 2025 (0.01) to Feb. 2026 (0.00). It may suggest that Voyageur Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Voyageur Pharmaceuticals  (OTCPK:VYYRF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.02 0.02 0.01

Voyageur Pharmaceuticals Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.00
VYYRF
18GF Score
Voyageur Pharmaceuticals Ltd VYYRF
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Voyageur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2025 is calculated as

LT Debt to Total Assets (A: Nov. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Nov. 2025 )/Total Assets (A: Nov. 2025 )
=0.028/2.209
=0.01

Voyageur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Feb. 2026 is calculated as

LT Debt to Total Assets (Q: Feb. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Feb. 2026 )/Total Assets (Q: Feb. 2026 )
=0/2.161
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Voyageur Pharmaceuticals (VYYRF) has a LT-Debt-to-Total-Asset of 0.00 as of Feb. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Voyageur Pharmaceuticals and its competitors.
Is Voyageur Pharmaceuticals' LT-Debt-to-Total-Asset too high?
Voyageur Pharmaceuticals' current LT-Debt-to-Total-Asset is 0.00. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Voyageur Pharmaceuticals' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current LT-Debt-to-Total-Asset is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score

Get the complete analysis for VYYRF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price